Interestingly, when the 584 node-negative tumours were considered, the first-step regression showed that c Kit ranked second among the six-marker signature (Table 3) that correctly classified 80.95% of the patients (sensitivity 80.4%, specificity 83.8%, area under ROC curve 0.960) (Figure 6) in the metastatic or metastasis-free subsets. Here, KIT is linked to neoplasm.